127 related articles for article (PubMed ID: 38426611)
21. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.
Macías-Rodríguez RU; Solís-Ortega AA; Ornelas-Arroyo VJ; Ruiz-Margáin A; González-Huezo MS; Urdiales-Morán NA; Román-Calleja BM; Mayorquín-Aguilar JM; González-Regueiro JA; Campos-Murguía A; Toledo-Coronado IV; Chapa-Ibargüengoitia M; Valencia-Peña B; Martínez-Cabrera CF; Flores-García NC
World J Gastroenterol; 2022 Oct; 28(37):5444-5456. PubMed ID: 36312835
[TBL] [Abstract][Full Text] [Related]
22. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
23. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
24. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
Armandi A; Rosso C; Younes R; Leeming DJ; Karsdal MA; Caviglia GP; Pérez-Diaz-Del-Campo N; D'Amato D; Abdulle A; Nicolosi A; Castelnuovo G; Saracco GM; Ribaldone DG; Bugianesi E
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675579
[No Abstract] [Full Text] [Related]
25. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
26. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
27. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
28. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
[TBL] [Abstract][Full Text] [Related]
30. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease.
Madsen BS; Thiele M; Detlefsen S; Kjaergaard M; Møller LS; Trebicka J; Nielsen MJ; Gudmann NS; Leeming DJ; Karsdal MA; Krag A;
Aliment Pharmacol Ther; 2021 Sep; 54(5):699-708. PubMed ID: 34251031
[TBL] [Abstract][Full Text] [Related]
31. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
Hashimoto Y; Hamaguchi M; Okamura T; Nakanishi N; Obora A; Kojima T; Fukui M
J Diabetes Investig; 2022 Feb; 13(2):308-316. PubMed ID: 34561962
[TBL] [Abstract][Full Text] [Related]
32. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
33. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.
Erhardtsen E; Rasmussen DGK; Frederiksen P; Leeming DJ; Shevell D; Gluud LL; Karsdal MA; Aithal GP; Schattenberg JM
JHEP Rep; 2021 Aug; 3(4):100317. PubMed ID: 34466796
[TBL] [Abstract][Full Text] [Related]
34. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
[TBL] [Abstract][Full Text] [Related]
35. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
Liu M; Qiu H; Zhang W; Mei T; Tang S; Gao Y; Zhu Y; Huang X; Yu H
J Gastroenterol Hepatol; 2023 Jul; 38(7):1018-1027. PubMed ID: 37287367
[TBL] [Abstract][Full Text] [Related]
37. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
38. Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria.
Liu Y; Chai S; Zhang X
J Diabetes; 2024 Feb; 16(2):e13501. PubMed ID: 37974383
[TBL] [Abstract][Full Text] [Related]
39. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
40. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
